

# Quantel

## PRESS RELEASE

Les Ulis, May 2, 2017

### FIRST-QUARTER REVENUES

For the first quarter of 2017, the QUANTEL Group is reporting €15.4 million of revenues, down 8% compared with the same period the previous year, which included billing for a €2.9 million tender in India in January. Excluding revenues for India, growth for the first quarter comes out at 11.6%.

#### First-quarter consolidated revenues

Revenues (€M)	2016	2017 <sup>(1)</sup>	Change	Change excl. India tender
First quarter	16.7	15.4	-7.9%	+11.6%
<i>Of which</i>				
<i>Industrial and Scientific Products</i>	5.0	6.1	+20.1%	+20.1%
<i>Major Contracts</i>	2.7	2.5	-7.7%	-7.7%
<i>Medical / Ophthalmology</i>	9.0	6.8	-23.8%	+13.3%

(1) Unaudited provisional figures

#### Industrial and Scientific Division

The Industrial and Scientific Division achieved 20.1% revenue growth in the first quarter of 2017 compared with the first quarter of 2016, which is encouraging following the industrial market's contraction in 2016.

#### Major Contracts

The major contracts - MegaJoule and military - are making good progress and moving forward in line with the schedules set.

#### Ophthalmology Division

The Ophthalmology Division's sales benefited from the billing recorded in January 2016 following the major tender won in India for a total of €2.9 million. This non-recurring sale was not renewed and this is reflected in a 23.8% drop in revenues. However, excluding India, revenues are up 13.3%, thanks in particular to the good start made by the new Easyret product.

In view of this first quarter, the Company is maintaining its objective to keep full-year revenues at a very similar level to 2016 by offsetting the absence of the Indian contract through growth for the Industrial and Scientific Division and the Ophthalmology Division.

**Next date:** half-year revenues on July 27, 2017

1 / 1

Founded in 1970, Quantel is one of the world's leading specialists in laser technology for scientific (laboratories and universities), industrial (material processing, process analytics, marking) and medical (ophthalmology) markets. With design and manufacturing facilities in France and the US, the Quantel Group achieved in 2016 a turnover of 63 M€, with over 65% worldwide, divided into scientific and industrial laser applications (52%) and medical applications (48%).

Quantel shares are listed on the Euronext Paris C Compartment. FR0000038242 – QUA [www.quantel.fr](http://www.quantel.fr)



**Quantel**  
Laurent Schneider-Maunoury  
General Manager  
Tel. +33(0) 1 69 29 17 00  
info@quantel.fr

**Quantel**  
Luc Ardon  
CFO  
Tel. +33(0) 1 69 29 17 00  
info@quantel.fr

**Calyptus**  
Mathieu Calleux  
Investor Relations  
Tel. +33(1) 53 65 37 91  
quantel@calyptus.net